# Nektar Therapeutics

Type: Company (NKTR)

Source: GetYourBrief — https://getyourbrief.com/entity/nektar-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/nektar-therapeutics

## Timeline

- **2026-04-20**: Lead Plaintiff Deadline — Final date for investors to petition the court to lead the Enphase class action.
- **2026-03-22**: Enphase Suit Filed — Pomerantz LLP files class action litigation against Enphase Energy in federal court.
- **2026-03-22**: Litigation Expansion — Pomerantz confirms additional filings and alerts for Enphase and Nektar Therapeutics.
- **2026-03-22**: Enphase Energy Filing — Pomerantz LLP files a separate class action against Enphase Energy alleging securities fraud.
- **2026-03-22**: Secondary Nektar Notice — A follow-up announcement clarifies the class period and lead plaintiff deadline for Nektar investors.
- **2026-03-21**: Litigation Launch — Pomerantz LLP officially announces class action litigation against Nektar Therapeutics.
- **2026-03-21**: Litigation Filed — Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
- **2026-03-21**: Nektar Litigation Announced — Pomerantz LLP announces the first class action filing against Nektar Therapeutics.
- **2026-03-18**: Insider Sale — Director Thurman Rodgers sells 137,250 shares of Enphase stock.
- **2026-03-12**: Nektar Financial Update — Nektar files updated results of operations and financial condition reports.
- **2026-03-09**: Initial Filing — Pomerantz LLP commences class action proceedings against Enphase Energy.
- **2026-02-10**: Nektar Disclosure — Nektar Therapeutics issues Regulation FD disclosure regarding its business operations.
- **2026-02-03**: Enphase Financials — Enphase Energy files results of operations with the SEC, highlighting market challenges.
- **2022-04-18**: Partnership Termination — BMS and Nektar officially end their global clinical development collaboration.
- **2022-03-14**: Phase 3 Failure — Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.

## Recent coverage (5 stories, network-wide)

### Pomerantz LLP Targets Nektar and Enphase in New Securities Class Actions
2026-03-22 02:52:54 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has initiated class action litigation against Nektar Therapeutics and Enphase Energy, alleging securities fraud and misleading statements. These filings highlight a growing trend of legal scrutiny in the biotech and renewable energy sectors as companies navigate volatile market conditions and regulatory shifts.
Full story: https://getfinancebrief.com/story/pomerantz-llp-nektar-enphase-class-action-litigation

### Pomerantz LLP Initiates Securities Class Action Against Enphase Energy
2026-03-22 02:52:19 · Sector: climate · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has filed a class action lawsuit against solar technology leader Enphase Energy, alleging securities law violations following a period of significant stock volatility. The litigation marks a critical regulatory challenge for the renewable energy sector as it navigates a broader market downturn.
Full story: https://getclimatebrief.com/story/pomerantz-enphase-energy-class-action-litigation

### Pomerantz LLP Files Class Action Against Nektar Therapeutics Over Disclosures
2026-03-22 02:52:13 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Full story: https://getbiobrief.com/story/nektar-therapeutics-class-action-litigation-pomerantz

### Pomerantz LLP Targets Nektar and Enphase in New Securities Class Actions
2026-03-22 02:45:17 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has initiated class action lawsuits against Nektar Therapeutics and Enphase Energy, alleging violations of federal securities laws. The litigation follows a series of financial disclosures and regulatory filings in early 2026 that triggered significant market volatility for both companies.
Full story: https://getlegalbrief.com/story/pomerantz-llp-nektar-enphase-class-action

### Biotech and Deep Tech Reach Critical Inflection Points in Q4 Earnings
2026-03-13 00:13:52 · Sector: startups · Sentiment: Positive · Impact: 7/10 · Sources: 15

The Q4 2025 earnings cycle marks a pivot toward commercial maturity for high-growth ventures, highlighted by Mineralys Therapeutics' FDA filing and EHang's first GAAP-profitable quarter. These results signal a de-risking phase for investors as pre-revenue startups transition into regulated, revenue-generating entities.
Full story: https://getstartupbrief.com/story/biotech-deep-tech-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.